Shorter course of trastuzumab could be an option for women with HER2+ early breast ca
Women with HER2-positive early breast cancer with small tumours have similar disease-free survival and lower risk of cardiac toxicity with a nine-week course of adjuvant trastuzumab compared to those treated for one year, according to a subgroup analysis of the Short-HER trial reported at ESMO 2018 Congress in Munich.
More... |
All times are GMT -7. The time now is 08:38 AM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021